GA is a leading cause of visual impairment affecting 5 million people worldwide. As the result of population growth and ageing, the numbers of people affected by AMD and GA are expected to increase considerably over the next few decades. GA is responsible for approximately 20% of all cases of legal blindness in the United States and 26% of cases in the United Kingdom. With no approved treatments to prevent or slow its progression and the number of people affected expected to increase, GA represents a significant unmet medical need.
Many studies have been conducted reporting prevalence and/or incidence data for late- AMD (GA and neovascular AMD) in different countries and regions around the world. As the numbers of those impacted by AMD and GA are forecast to increase in the decades ahead, in line with population growth and ageing, it is increasingly important to gather current statistics on a national and regional basis to inform healthcare policy and research into the future.